Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Alexandria Real Estate Equities is the largest owner and operator of life science real estate in North America, with 73.8 million SF of high-quality laboratory and office space concentrated in AAA innovation clusters (Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, New York City). The company serves as mission-critical infrastructure for pharmaceutical, biotech, and medical device tenants requiring specialized lab facilities with 18-foot ceiling heights, 150+ lbs/SF floor loads, and dedicated HVAC systems that cannot be easily replicated.
Alexandria generates cash flow through long-term triple-net leases (average 8-10 year terms) with investment-grade pharmaceutical companies (Pfizer, Moderna, Bristol Myers Squibb) and well-funded biotech tenants. The company commands premium rents ($60-$120 PSF depending on market) due to high barriers to entry—specialized lab infrastructure requires $200-$400 PSF in tenant improvements versus $50-$75 PSF for conventional office. Pricing power stems from supply constraints in core clusters where zoning, utility capacity, and proximity to research institutions limit new development. The REIT structure requires 90% of taxable income distribution, funded by $1.4B annual operating cash flow. Development pipeline (4.8M SF) targets 200+ basis point spreads over stabilized cap rates.
Same-store NOI growth driven by annual rent escalators (2.5-3.5%) and occupancy in core clusters
Development pipeline leasing velocity and delivery timing (currently 4.8M SF under construction)
Cap rate compression/expansion in life science assets versus 10-year Treasury spreads
Biotech funding environment (IPO volumes, venture capital deployment, M&A activity)
Tenant credit quality and lease renewal spreads in Greater Boston and San Francisco markets
Biotech funding cycle volatility—prolonged bear markets in life science venture capital and IPOs reduce tenant formation and expansion demand, particularly for sub-100K SF requirements
Regulatory risk from drug pricing legislation (IRA provisions) potentially reducing pharmaceutical R&D budgets and long-term space needs
Geographic concentration in San Francisco Bay Area (30%+ of NOI) exposes portfolio to California tax policy, permitting delays, and regional economic shocks
Increased competition from BXP, KRC, and private developers entering life science conversions in Greater Boston and San Diego, compressing rent growth
Tenant vertical integration risk—large pharmaceutical companies building owned campuses rather than leasing (e.g., Amgen, Gilead owned facilities)
Obsolescence risk if lab specifications evolve (e.g., shift to AI-driven drug discovery reducing wet lab demand)
0.82 debt/equity ratio with $8B total debt creates refinancing risk if credit spreads widen significantly
Negative net income (-48.2% margin) and negative ROE (-8.6%) reflect non-cash impairments and development accounting, but signal balance sheet stress if sustained
Development pipeline funding gap—$2.5B under construction requires asset sales, equity raises, or credit line draws if capital markets remain closed
moderate - Life science demand is less cyclical than traditional office due to pharmaceutical R&D spending driven by aging demographics and chronic disease prevalence rather than GDP growth. However, biotech tenant demand correlates with venture capital availability and IPO markets, which contract during recessions. Investment-grade pharma tenants (60%+ of ABR) provide stability through downturns.
High sensitivity through multiple channels: (1) REIT valuation multiples compress as 10-year Treasury yields rise and cap rates expand, reducing price/FFO multiples; (2) Development economics deteriorate as construction financing costs increase (currently $2.5B development pipeline at risk if rates spike); (3) Biotech tenant demand weakens when venture capital becomes expensive and IPO windows close. The company's 0.82 debt/equity ratio and $8B debt stack means 100bps rate increase adds ~$40-50M annual interest expense on floating rate debt and refinancings.
Moderate exposure to biotech credit risk. While 60% of tenants are investment-grade pharmaceutical companies with strong balance sheets, 40% are venture-backed biotech firms dependent on capital markets access. Credit tightening reduces biotech funding, leading to space give-backs, bankruptcy risk, and lower leasing demand. However, triple-net lease structure and tenant improvement recapture provisions mitigate downside.
value - Trading at 0.6x price/book and 15.5% FCF yield despite negative near-term earnings suggests deep value opportunity if life science fundamentals stabilize. Attracts contrarian investors betting on biotech cycle recovery and REIT multiple re-rating. Dividend yield (implied ~5-6% based on REIT payout requirements) appeals to income investors, though distribution sustainability depends on AFFO coverage.
high - 45.2% decline over past year and 30% drop in six months reflects elevated beta to interest rates, biotech funding cycles, and REIT sector sentiment. Life science REIT valuations exhibit 1.3-1.5x beta to 10-year Treasury moves.
